Suggestions in Courses

See all course results

Suggestions in News

  • No suggestions found.

Suggestions in Events

See all events results
My Prospectus (0) Staff Students
Professor Jameel Inal

Jameel Inal is a Professor of Immunobiology for the School of Human Sciences.

Jameel leads the Cell Communication in Disease Pathology research group.

Jameel Inal smiling at the camera

Jameel Inal

Prof. Inal has a Microbiology BSc from King's College London and a Virology MPhil. He focused on vaccine research for his PhD at Porton Down (Centre for Applied Microbiology and Research, part of the Public Health Laboratory Service and now Public Health England, Centre for Emergency Preparedness and Response). Here he gained experience in public health microbiology (up to ACDP category 3 pathogens and genetic manipulation thereof).

He also worked as a postdoctoral researcher in the Immunology Unit at the London School of Hygiene and Tropical Medicine, MRC Immunochemistry Unit at Oxford and was a Senior Research Fellow in the Department of Biomedicine at the University Hospital Basel, Switzerland.

He was Professor of Immunology at London Met from 2007 to 2017 and founded the Cellular and Molecular Immunology Research Centre. He was also Professor of Biomedical Science and Associate Dean of Research at the School of Life and Medical Sciences, University of Hertfordshire from 2017 to 2020. In 2020, Professor Inal returned to London Met as Professor of Immunobiology. He is still a visiting Professor of Biomedical Science at the University of Hertfordshire.

Positions and memberships 

  • Member of the Biochemical Society (2000-2017)
  • Member of the American Association for Immunologists (2002-2018)
  • Member of Federation of American Societies for Experimental Biology (2002-2018)
  • Fellow of the Royal Society of Biology (FRSB) since 2006
  • Chartered Biologist (CBiol) since 2006 
  • Member of the European Complement Network since 2006
  • Founding member of the International Society for Extracellular Vesicles (ISEV) since 2012
  • On the Biochemical Society Database of Expertise since 2012
  • Guest Associate Editor for Frontiers in Immunology (Microbial Immunology) since 2014
  • Guest Associate Editor for Frontiers in Microbiology since 2014 
  • Editorial Board Member of Scientific Reports (Nature Publishing Group) since 2017
  • Expert Evaluator for the European Commission since 2018
  • Member of the Royal Society for Tropical Medicine and Hygiene (2022-)
  • Review Editor for Frontiers in Immunology (Molecular Innate Immunity)
  • Invited editor of the special issues, ‘Therapeutic Applications of Extracellular Vesicles’ in Cells, (IF 5.7) Special Issue of Therapeutic Applications of Extracellular Vesicles and ‘Extracellular Vesicles and the Tumour Microenvironment in Cancers, (IF 6.2) 

 

Professor Inal has taught widely within Biomedical Science, but with an emphasis on the immunology of infectious diseases and cancer, at both undergraduate and postgraduate level. He has supervised thirteen PhD students to completion and forty eight MSc projects.

Professor Inal’s research investigates the role of extracellular vesicles and intercellular communication in disease mechanisms with a view to apply this knowledge to provide translational solutions across a wide area of biomedicine, ranging from infectious disease to cancer. His lab comprises six PhD students and a postdoctoral researcher.

 

  • Ansa-Addo, E.A., Pathak, P., McCrossan, M.V, Rossi, I., V., Abdullahi, M., Stratton, D., Lane, S., Ramirez, M.I., Inal, J.M. (2024) Monocyte-derived Extracellular Vesicles, stimulated by Trypanosoma cruzi, enhance cellular invasion in vitro, via activated TGF-β1. J Extracell Vesicles. 13(11):e70014.
  • Lange, S., Inal, J.M., Kraev, I., Alwyn Dart, D., and Uysal-Onganer, P. (2024) Low Magnetic Field Exposure alters Prostate Cancer Cell Properties. Biology 13(9), 734.
  • Welsh, J. A., Goberdhan, D. C. I., O’Driscoll, L., Buzas, E. I., Blenkiron, C., Bussolati, B., Cai, H.,
    Di Vizio, D., Driedonks, T. A. P., Erdbrügger, U., Falcon-Perez, J. M., Fu, Q.-L., Hill, A. F., Lenassi, M., Lim, S. K., Mahoney, M. G., Mohanty, S., Möller, A., Nieuwland, R., … Witwer, K. W. (2024). Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. Journal of Extracellular Vesicles, 13, e12404.
  • Goh, S. and Inal, J.M. (2024) Membrane vesicles of Clostridioides difficile and other Clostridial species. In series: Advances in Microbiology, Infectious Diseases and Public Health. Book title: Updates on Clostridioides difficile in Europe, Vol 4136, pp315-327, Springer Nature.
  • Lange, S. and Inal, J.M. (2023) Animal Models of Human Disease. Int. J. Mol. Sci. 24(21), 15821
  • Jorfi, S., Ansa-Addo, E.A., Mariniello, K., Warde, P., Bin Senian, A.A., Stratton, D., Bax, B.E., Levene, M., Lange, S., and INAL, J.M. (2023). A Coxsackievirus B1-mediated nonlytic Extracellular Vesicle-to-cell mechanism of virus transmission and its possible control through modulation of EV release.
    J Gen Virol. 104(9).
  • Rossi, I.V., Nunes, M.A.F., Sabatke, B., Ribas, H.T., Winnischofer S.M.B., Ramos, A.S.P., INAL, J.M., and Ramirez, M.I. (2022) An induced population of Trypanosoma cruziepimastigotes more resistant to complement lysis promotes a phenotype with greater differentiation, invasiveness and release of extracellular vesicles Front. Cell. Infect. Microbiol. 12:1046681.
  • INAL, J. Paizuldaeva A, Terziu E. (2022) Therapeutic use of calpeptin in COVID-19 infection. Clin Sci (Lond). Oct 28;136(20):1439-1447
  • Stratton, D. Malibha-Pinchbeck, M. and INAL, J. (2022) Extremely low-frequency magnetic fields significantly enhance the cytotoxicity of methotrexate and can reduce migration of cancer cell lines via transiently induced plasma membrane damage. Biochem. Biophys. Res. Commun. 626, 192-199
  • INAL, J.M., Hristova, M., and Lange, S. (2022) A Pilot Study on Peptidylarginine Deiminases and Protein Deimination in Animal Cancers across Vertebrate Species. Int. J. Mol. Sci. 23(15):8697.
  • De Sousa K.P., Rossi, I., Abdullahi, M., Ramirez, M.I., Stratton, D., and INAL, J.M. (2022) Isolation and characterization of extracellular vesicles and future directions in diagnosis and therapy. WIREs Nanomedicine & Nanobiotechnology Jul 27:e1835. 
  • Laich A, Patel H., Zarantonello A., Sim, R.B., Inal, J.M. (2022) C2 by-pass: Cross-talk between the complement classical and alternative pathways. Immunobiology. 227(3):152225.
  • Stotz, H.U., Brotherton, D. and INAL, J.M. (2022) Communication is key: Extracellular vesicles as mediators of infection and defence during host-microbe interactions in animals and plants FEMS Microbiol. Rev.46(1)fuab044.
  • Bernstein DE, Piedad J, Hemsworth L, West A, Johnston ID, Dimov N, INAL, J.M., and Vasdev N. (2021) Prostate cancer and microfluids. Urol Oncol. S1078-1439(21)00120-4. 
  • INAL, J. (2020) Biological Factors Linking ApoE ε4 Variant and Severe COVID-19. Curr Atheroscler Rep.(11):70.
  • INAL, J. (2020) Complement-mediated Extracellular Vesicle release as a measure of endothelial dysfunction and prognostic marker for COVID-19 in peripheral blood - Letter to the Editor. Clin Hemorheol Microcirc. 2020;75(4):383-386.
  • INAL, J. (2020) COVID-19 comorbidities, associated procoagulant extracellular vesicles and venous thromboembolisms: a possible link with ethnicity? Br J Haematol. 10.1111
  • INAL J.M. (2020) Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy. Clin Sci (Lond). 134(12):1301-1304.
  • Uysal-Onganer, P., MacLatchy, A., Mahmoud, R., Kraev, I., Thompson, P.R., INAL, J.M., Lange, S. (2020) Peptidylarginine deiminase isozyme-specific PAD2, PAD3 and PAD4 inhibitors differentially modulate extracellular vesicle signatures and cell invasion in two glioblastoma multiforme cell lines. International Journal of Molecular Sciences 21(4). pii: E1495
  • Antwi-Baffour, S., Malibha-Pinchbeck, M., Stratton, D., Lange, S., INAL, J.M. (2019) Plasma mEV levels in Ghanain malaria patients with low parasitaemia are higher than those of healthy controls, raising the potential for parasite markers in mEVs as diagnostic targets. J. Extracell. Vesicles 9(1):1697124
  • Kosgodage U.S., Matewele P., Awamaria B., Kraev I., Warde P., Mastroianni G., Nunn A.V., Guy G.W., Bell J.D., INAL, J.M., Lange S. (2019) Cannabidiol Is a Novel Modulator of Bacterial Membrane Vesicles. Front Cell Infect Microbiol. 10;9:324.
  • Kosgodage U., Matewele P, Mastroianni G, Kraev I, Brotherton D, Awamaria B, Nicholas AP, Lange S, and INAL J.M. (2019) Peptidylarginine Deiminase Inhibitors Reduce Bacterial Membrane Vesicle Release and Sensitize Bacteria to Antibiotic Treatment. Front Cell Infect Microbiol. 9:227.
  • Sisa, C. Kholia, S., Naylor, J., Herrera Sanchez, M., Bruno, S., Deregibus, M., Camussi, G., INAL, J.M., Lange, S., Hristova, M. (2019) Mesenchymal Stem-Cell derived Extracellular Vesicles reduce Hypoxia-Ischemia Induced Perinatal Brain Injury. Frontiers Physiol. 10:282.
  • Thery, C….Inal, J.M…et al., (2018) Minimal Information for studies of Extracellular Vesicles (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7:1, 1535750. 
  • Kosgodage, U., Onganer, P.U. Maclathcy, A., Kraev. I., Chatterton, N.P., Nicholas, A.P., INAL, J.M. and Lange, S. (2018) Peptidylarginine Deiminases post-translationally deiminate prohibitin and modulate Extracellular Vesicle Release and microRNAs in Glioblastoma Multiforme. Int. J. Mol. Sci. 20(1). pii: E103.
  • Kosgodage, U.S., Uysal-Onganer, P., Maclathcy, A., Mould, R. Nunn, A.V., Guy, G.W., Kraev. I., Chatterton, N.P., Thomas, E. L Thomas, INAL, J.M., Bell, J.D., and Lange, S. (2018) Cannabidiol modulates Extracellular Vesicle Export of miR21 and miR126 1 and reduces Prohibitin Protein in Glioblastoma Multiforme Cells. Transl. Oncol. 12(3):513-522.
  • Kosgodage, U., Mould, R., Henley, A.V., Nunn, A.V., Guy, G.W., Thomas, E. L, INAL, J., Bell, J. and Lange, S. (2018) Cannabidiol (CBD) is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release. Front. Pharmacol. 9 doi: 10.3389/fphar.2018.00889
  • Gavinho B., Rossi I.V., Evans-Osses I., INAL J., Ramirez, M.I. (2018) A new landscape of host–protozoa interactions involving the extracellular vesicles world. Parasitology doi: 10.1017/S0031182018001105
  • Lange S., Kholia S., Kosgodage U.S., INAL, J.M. (2017) Treatment of Prostate Cancer Using Deimination Antagonists and Microvesicle Technology. In: Protein Deimination in Human Health and Disease, Volume II (Bhattacharya, S; Nicholas, A (Eds.), Chapter 22. Springer; 2nd ed. 2017 edition (10th Nov 2017). ISBN-13: 978-3319582436; ISBN-10: 3319582437.
  • Lange, S., Gallagher, M., Kholia, S., Kosgodage, U.S., Hristova, M., Hardy, J. and INAL, J.M. (2017) Peptidylarginine Deiminases – Roles in Cancer and Neurodegeneration and Possible Avenues for Therapeutic Intervention via Modulation of Exosome and Microvesicle (EMV) Release? Int. J. Mol. Sci. 18, 1196; doi:10.3390/ijms18061196
  • Kosgodage, U., Trindade, R.P., Thompson, P.R., INAL, J.M. and Lange, S. (2017) Combined inhibiton of peptidylarginine deiminase and protein kinase C-mediated microvesicle release significantly enhances efficacy of cancer chemotherapy. Invited submission to special edition on Microvesicles. Int. J. Mol. Sci. 18(5). pii: E1007
  • Moore, C., Kosgodage, U, Lange, S., INAL, J.M. (2017) The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy. Int. J. Cancer  Invited Review. 141:428-436 doi: 10.1002/ijc.30672
  • Evans-Osses, I., Mojoli, A., Monguio-Tortajada, M., Marcilla, A., Aran, V., INAL, J.M. Borras, F.E., and Ramirez, M.I. (2017) Microvesicles released from Giardia intestinalis disturb host-pathogen response in vitro. Eur. J. Cell Biol. 96,131-142
  • Hayes, L., INAL, J.M., Stratton, D. (2015) Re: Inflamed macrophage microvesicles induce insulin resistance in human adipocytes. (Letter to Editor) Nutr. Metab. 12:21
  • Jorfi, S., Ansa-Addo, E.A.,  Kholia, S., Stratton, D., Valley, S., Lange, S.,  INAL, J. (2015) Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces the dose of docetaxel required to limit tumour growth in a xenograft mouse model of prostate cancer. Sci. Rep. 5:13006.
  • Liu, L.W.Y., Virdee, B.S.,  INAL, J. , Steer, M.B.  (2015) Microfabrication of conical micro-funnels for drug delivery applications. Micro & Nano Letters 10, 355-357. 
  • Kholia, S., Thompson, P.R., Nicholas, A.P., INAL, J., Lange, S. (2015) A novel role for peptidylarginine deiminases (PADs) in microvesicle release: therapeutic potential for PAD inhibitors to sensitize prostate cancer cells to chemotherapy. J. Extracell. Vesicles. 2015 4:26192.
  • An T, Qin S, Xu Y, Tang Y, Huang Y, Situ B, INAL, J.M., Zheng L. (2015) Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. J. Extracell. Vesicles. 2015 4:27522.
  • Stratton D, Moore C, Antwi-Baffour S, Lange S, INAL, J. (2015) Microvesicles released constitutively from prostate cancer cells differ biochemically and functionally to stimulated microvesicles released through sublytic C5b-9. Biochem. Biophys., Res., Commun.. 460, 589-95.
  • Stratton D, Moore C, Zheng L, Lange S, INAL, J. (2015) Prostate cancer cells stimulated by calcium-mediated activation of protein kinase C undergo a refractory period before re-releasing calcium-bearing microvesicles. Biochem. Biophys. Res. Commun. 460, 511-7.
  • Kim, D.-K., ….INAL, J…..Gho, Y.S. (2015) EVpedia: A community web portal for extracellular vesicles research. Bioinformatics. 31, 933-9.
  • Stratton D, Lange S, Kholia S, Jorfi S, Antwi-Baffour S, INAL J. (2014) Label-free real-time acoustic sensing of microvesicle release from prostate cancer (PC3) cells using a Quartz Crystal Microbalance. Biochem Biophys Res. Commun.  453, 619-624.
  • Dinasarapu, A.R., Chandrasekhar, A., INAL, J. and Subramaniam S. (2013) Complement C2. UCD Molecule Pages, 2, (2) doi:10.6072/H0.MP.A004234.01
  • INAL J.M., Kosgodage, U., Azam, S., Stratton, D., Antwi-Baffour, S., Lange, S. (2013) Blood/plasma secretome and microvesicles. Biochim. Biophys. Acta. 1834, 2317-2325.
  • INAL, J.M., Fairbrother, U. and Heugh, S. (2013) Microvesiculation and Disease. Biochem. Soc. Trans. 41, 237-240.  
  • INAL, J.M., Ansa-Addo, E.A. and Lange, S. (2013) Interplay of host-pathogen microvesicles and their role in infectious disease. Biochem. Soc. Trans. 41, 258-262.
  • INAL, J.M. and Jorfi, S. (2013) The role of microvesicles in cancer progression and drug resistance. Biochem. Soc. Trans. 41, 293-298.
  • INAL, J.M. and Jorfi, S. (2013) Coxsackievirus B transmission and possible new roles for extracellular vesicles. Biochem. Soc. Trans. 41, 299-302. 
  • Stratton, D., Lange, S. and INAL, J.M. (2013) Pulsed extremely low-frequency magnetic fields stimulate microvesicle release from human monocytic leukaemia cells. Biochem. Biophys. Res. Commun. 430, 470-475. 
  • INAL, J.M., Ansa-Addo EA, Stratton D, Kholia S, Antwi-Baffour SS, Jorfi S, Lange S. (2012) Microvesicles in Health and Disease. Arch. Immunol. Ther. Exp. 60, 107-21.
  • Hina, K., Simpson, R….INAL, J.M. …and Mathivanan, S. (2012) Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation. Plos Biology 10, e1001450.
  • Cestari I, Ansa-Addo E, Deolindo P, INAL, J.M., Ramirez MI. (2012) Trypanosoma cruzi immune evasion mediated by host cell-derived microvesicles. J Immunol. 188, 1942-52.
  • INAL, J.M. (2012) Micro matters. Public Service Review European Science and Technology 14, 172
  • INAL, J.M. (2011) A new patent for partnership Public Service Review: UK Science and Technology 2, 156-157
  • Grant R, Ansa-Addo E, Stratton D, Antwi-Baffour S, Jorfi S, Kholia S, Krige L, Lange S, INAL J. (2011) A filtration-based protocol to isolate human plasma membrane-derived vesicles and exosomes from blood plasma. J Immunol Methods. 371, 143-51.
  • INAL, J.M. (2010) Improving cellular understanding at CMIRC. Public Service Review: UK Science and Technology 1, 150-151
  • Heugh, S., Hudson, K. INAL, J.M. (2010) Online material for ‘Immunology’ A. Hall and C. Yates, Eds.
  • A. Hall and C. Yates Eds. In ‘Immunology,’ Fundamentals of Biomedical Science
  • Ansa-Addo, E.A., Lange, S., Stratton, D., Antwi-Baffour, S., Cestari, I., Ramirez, M.I., mcCrossan, M.V., Inal, J.M. (2010) Human plasma membrane-derived vesicles halt prolieration and induce differentiation of THP-1 acute monocytic leukemia cells. J. Immunol. 185, 5236-46.
  • Hind E, Heugh S, Ansa-Addo EA, Antwi-Baffour S, Lange S, INAL J. (2010) Red cell PMVs, plasma membrane-derived vesicles calling out for standards. Biochem. Biophys. Res. Commun. 399, 465-9
  • Antwi-Baffour S, Kholia S, Aryee YK, Ansa-Addo EA, Stratton D, Lange S, INAL JM. (2010) Human plasma membrane-derived vesicles inhibit the phagocytosis of apoptotic cells-possible role in SLE. Biochem. Biophys. Res. Commun. 98, 278-83.
  • Evans-Osses I, Ansa-Addo EA, INAL, J.M., Ramirez MI. (2010) Involvement of lectin pathway activation in the complement killing of Giardia intestinalis. Biochem. Biophys. Res. Commun. 395, 382-6.
  • Cestari, I., Krarup, A., Sim, R.B., INAL, J.M.* and Ramirez, M.I.* (2009) Role of early lectin pathway activation in the complement-mediated killing of Trypanosoma cruzi. Mol. Immunol. 47, 426-437
  • Cestari, I., Evans-Osses, I., Freitas, J.C., INAL, J.M.* and Ramirez, M.I.* (2008) Complement C2 Receptor Inhibitor Trispanning confers an increased ability to resist complement-mediated lysis in Trypanosoma cruzi. J. Inf. Dis. 198, 1276
  • Moll, S., Lange, S., Mihatsch, M.J., Dragic, Z., Schifferli, J.A.* and INAL, J.M. (2006) Complement C2 receptor inhibitor trispanning (CRIT) is expressed on podocytes in normal human kidney and upregulated in membranous glomerulonephritis. Kidney Int.  69, 1961
  • Hui, K.-M.*, Schifferli, J.A. and INAL, J.* (2006) CRIT peptide interacts with factor B and interferes with the alternative pathway activation. Biochem. Biophys. Res. Commun. 344, 308
  • INAL, J.M.  (2005) CRIT, (complement C2 receptor inhibitor trispanning), from man to schistosome in "Complement and Human Diseases" Springer Seminars in Immunopathology 27, 320.
  • INAL, J.M.* Miot, S. and Schifferli, J.A. (2005) The complement inhibitor CRIT undergoes ligand-mediated endocytosis via clathrin-coated pits. Exp. Cell Res. 310, 54.
  • Hui K.M.*, Orriss G.L., Schirmer T, Magnadottir B, Schifferli J.A, INAL J.M.* (2005) Expression of functional recombinant von Willebrand factor-A domain from human complement C2: potential binding site for C4 and CRIT. Biochem. J. 389, 863
  • INAL, J,* Hui, K.-M., Miot, S., Lange, S, Ramirez, M.I., Schneider, B., Krueger, G., and Schifferli, J.A. (2005) Complement C2 Receptor Inhibitor Trispanning: A novel human complement inhibitory receptor. 
  • J. Immunol., 174, 356 Highlighted in “In this Issue” J. Immunol. 174, 1-2. A small number of papers regarded by reviewers and editors as the top 10% in their field are highlighted in this page section.
  • INAL, J,* (2004) Parasite interaction with host complement: beyond attack regulation.  Trends Parasitol. 20, 4
  • Horakova, E., Gasser, O., Sadallah, INAL, J., S., Bourgeois, G., Ziekau, I., Klimkait, T., Schifferli, J.A.* (2003) Complement mediates the binding of HIV immune complexes and HIV alone to erythrocytes.  J. Immunol. 173, 4236.
  • INAL, J,* Pascual, M., Lesavre, P., and Schifferli, J.A. (2003) Complement inhibition in renal diseases. Nephrol. Dial. Transplant. 18, 237.
  • INAL, J.* (2003) Phage therapy: a reappraisal of bacteriophages as antibiotics. Arch. Immunol. Ther. Exp.  50
  • INAL, J.,* Schneider, B., Armanini, M., and Schifferli, J.A. (2003) A peptide derived from the parasite receptor, Complement C2 Receptor Inhibitor Trispanning, CRIT, suppresses immune complex-mediated inflammation in mice. J. Immunol 170, 4310.
  • INAL, J.* and Schifferli, J.A. (2002) Complement C2 receptor inhibitor trispanning (CRIT) and the Beta-chain of C4 share a binding site for complement C2. J. Immunol. 168, 5213.
  • INAL, J. (2001) PCT (Patent Cooperation Treaty) No. PCT/GB01/00085 filed on the CRIT receptor.
  • INAL, J.* and Sim, R.B. (2000) A Schistosoma protein, Sh-TOR, is a novel inhibitor of complement which binds human C2. FEBS Lett. 470, 131-134
  • INAL, J.* (1999) Schistosoma TOR (Trispanning Orphan Receptor), a novel, antigenic surface receptor of the blood-dwelling, Schistosoma parasite. Biochim. Biophys. Acta 1445, 283-298
  • INAL, J.,* Karunakaran, V. and Jones, D.R. (1996) Bacillus thuringiensis var. aizawai generalised transducing phage, HD248: restriction site map and potential for fine structure chromosomal mapping. Microbiology 142, 1409-1416
  • INAL, J. * and Karunakaran, V. (1996) 20, a temperate bacteriophage isolated from Bacillus anthracis exists as a plasmidial prophage. Current Microbiology 32, 171-175
  • INAL, J. and Bickle, Q. (1995) Sequence and immunogenicity of the 23-kDa transmembrane antigen of Schistosoma haematobium. Molecular and Biochemical Parasitology 74, 217-221
  • INAL, J., Karunakaran, V. and Burges, H.D. (1992) Generalised transduction in Bacillus thuringiensis var. aizawai. Journal of Applied Bacteriology 72, 87-90
  • INAL, J., Karunakaran, V. and Burges, H.D. (1990) Isolation and propagation of phages naturally associated with the aizawai variety of Bacillus thuringiensis. Journal of Applied Bacteriology 68, 17-21
  • INAL, J., Karunakaran, V. and Burges, H.D. (1989) Restriction map of Bacillus thuringiensis var. aizawai transducing phage, p634 in Fundamental and applied aspects of invertebrate pathology. eds. R.A. Samson, J.M. Vlak and D. Peters ISBN 90-9001340-7
  • Lee, D., Miles, R. and INAL, J. (1987) Antibiotic sensitivity and mutation rates to antibiotic resistance in Mycoplasma mycoides ssp. mycoides. Epidemiology and Infection 98, 361-368

Published Abstracts and Poster/Oral Presentations 

  • Lekkala H.R., Johnston, I.D., Dimov, N., and INAL, J.M. (2022) Developing microfluidic devices and systems for isolation and detection of extracellular vesicles, EVs Proceedings of Abstracts School of Physics, Engineering and Computer Science Research Conference 2022 Publ. Univ. of Hertfordshire.
  • Rossi, I.V., Sabatke, B., de Oliveira, A.C., INAL, J. and Ramirez, M. (2022) Participation of Extracellular Vesicles in the dynamics of T. cruzi infection (Paper Nr. 576294) presented at Federal University of Paraná, 3rd Symposium of Cellular and Molecular Biology 25th-27th October, 2022
  • R. de la Flor, M. Alavijeh and J. INAL (2021) Co-localization of amyloid beta plaques and exosome markers in the APP/PS1 mouse brain. Abstract 1310. Presented at AD/PDTM March 9th-14th, 2021, Barcelona, Spain 
  • Lekkala, H.R., Johnston, I., Dimov, N., INAL, J. (2020) Developing microfluidic devices and techniques for isolation and detection of extracellular vesicles (EVS)(Conference Paper). MicroTAS 2020 - 24th International Conference on Miniaturized Systems for Chemistry and Life Sciences, Pages 661-662 Virtual, Online; 4 October 2020 through 9 October 2020; Code 165714 
  • Sisa, C. Kholia, S., Naylor, J., Herrera Sanchez, M., Bruno, S., Deregibus, M., Camussi, G., INAL, J.M., Lange, S., Hristova, M. (2020) MSC derived extracellular vesicles reduce hypoxia-ischemia induced perinatal brain Injury. Presented at the Pediatric Academic Societies (PAS) 2020 Meeting, May 2-5, 2020, in Philadelphia, PA. 
  • Brotherton, D. and INAL, J.M. (2019) Investigating the Relationship Between Bacterial Vesicles and Biofilm Formation in E. coli UK EV meeting, December 10th, Crick Institute
  • Kosgodage, U.S., Matewele, P., Awamaria, B., Kraev, I., Warde, P., Mastroianni, G., Nunn, A., Guy, G. Bell, J., Brotherton,D., Nicholas, A. P., Lange,S. and INAL, J. M. (2019) Inhibitors of Peptidyl Arginine Deiminase and Cannabidiol Reduce Bacterial Membrane Vesicle Release and Sensitize Bacteria to Antibiotic Therapy. UK EV meeting, December 10th, Crick Institute
  • Sisa, C. Kholia, S., Naylor, J., Herrera Sanchez, M., Bruno, S., Deregibus, M., Camussi, G., INAL, J.M., Lange, S., Hristova, M. (2019) MSC derived extracellular vesicles reduce hypoxia ischaemia induced perinatal brain
  • Injury. Presented at Society for Neuroscience 2019 meeting, Chicago, October 19th-23rd.
  • Brotherton, D. and INAL, J.M. (2019) Investigating the relationship between bacterial vesicles and biofilm formation in E. coli. Presented at ‘EUROBIOFILMS 2019,’ Glasgow. European Society of Clinical Microbiology and Infectious Diseases.
  • Lange, S., INAL, J.M., Wray, S., Devine, M., Matarin, M., Nicholas, A.P., Jardy, J. (2017) Peptidylarginine Deiminases (PADs) – Novel Drug Targets for the Amelioration of Neurodegenerative Disease Progression - Modelled in Human iPSCs. Leonard Wolfson Experimental Neurology Centre Annual Symposium 2017. 20th  March, 2017, UCL Institute of Child Health, London, U.K.
  • Kosgodage, U., Lange, S., and INAL, J.M. (2016) Inhibitors of microvesicle release with the potential to enhance
  • effectivity of cancer chemotherapy. PW1.05 Journal of Extracellular Vesicles 2016, 5: 31552 - http://dx.doi.org/10.3402/jev.v5.31552. International Society of Extracellular Vesicles, Rotterdam, 4th-7th May.
  • Kosgodage, U., INAL, J.M., and Lange, S. (2016) Non-phagocytic epithelial cells take up microvesicles by macropinocytosis Journal of Extracellular Vesicles 2016, 5: 31552 - http://dx.doi.org/10.3402/jev.v5.31552. International Society of Extracellular Vesicles, Rotterdam, 4th-7th May.
  • S. Velkova, Johnston, S.L., INAL, J., McLean, G.R. (2015) Rhinovirus infection induces microvesicle release from cells. XVII International Symposium on Respiratory Viral Infection. XVII International Symposium on Respiratory Viral Infections. March 6 – 8, 2015 Pinnacle Vancouver Harbourfront Hotel Vancouver, British Columbia, Canada.
  • Contursi, C., INAL, J., Schiffelers, R.M., Campistol, J.M. and Tetta, C. (2014) Extracellular vesicles and exosomes from adult stem cells in the regeneration of organ injury. Journal of Extracellular Vesicles Vol 3 Abstract LB-609
  • 3rd International meeting of the International Society for Extracellular Vesicles, Rotterdam (2014)
  • INAL, J.M. and Stratton, D. (2014) Real time analysis of microvesiculation using a Quartz Crystal Microbalance. Journal of Extracellular Vesicles Vol 3 Abstract P1B-034.
  •  2nd International meeting of the International Society for Extracellular Vesicles, Boston
  • Jorfi, S. and INAL, J.M. (2013) Cancer cell expulsion of anticancer drugs through shedding of microvesicles: association with drug resistance and tumour survival. Journal of Extracellular Vesicles Vol 2 Abstract 142
  • Haidery, A. and INAL, J.M. (2013) Microvesicles and epithelial mesenchymal transition in the development of cancer. Journal of Extracellular Vesicles Vol 2 Abstract 141
  • Jorfi, S. and INAL, J.M. (2013) Coxsackie virus entry and spread in HeLa cells is aided by microvesicle release. Journal of Extracellular Vesicles Vol 2 Abstract 239
  • Stratton, D. and INAL, J.M. (2013) Extremely Low Frequency Magnetic Fields significantly enhance the potency of chemotherapeutic drugs for the targeted treatment of cancer. Journal of Extracellular Vesicles Vol 2 Abstract 143
  • Inal, J.M., Jorfi, S. (2012) Coxsackievirus B transmission and possible new roles for extracellular vesicles. Biochem. Soc. Trans. 41, 299-302   
  • Inal, J.M., Ansa-Addo, E.A., Lange, S. (2012) Interplay of host-pathogen microvesicles and their role in infectious disease. Biochem. Soc. Trans. 41, 258-262
  • Inal, J.M., Fairbrother, U., Heugh, S. (2012) Microvesiculation and disease Biochem. Soc. Trans. 41, 237-249
  • Jorfi, S., Inal, J.M. (2012) The role of microvesicles in cancer progression and drug resistance. Biochem. Soc. Trans. 41, 293-298
  • Grant, R.C., INAL, J.M. (2012) Isolation of microvesicles and exosomes by microfiltration and estimation of normal reference range in blood plasma. Microvesiculation and disease; 13-14 September 2012
  • Stratton, D. INAL, J.M. (2012) Characterisation of microvesicles released from cells constitutively and upon stimulation Microvesiculation and disease; 13-14 September 2012
  • Kholia, S, INAL, J.M. (2012) Human skeletal muscle-derived microvesicles induce apoptosis in highly metastatic prostate cancer cells Microvesiculation and disease; 13-14 September 2012
  • Haidery, A., INAL, J.M. (2012) Microvesicles and epithelial mesenchymal transition in the development of cancer Microvesiculation and disease; 13-14 September 2012 1st International meeting of the International Society for Extracellular Vesicles, Gothenburg
  • Grant, R., Ansa-Addo, A., Stratton, D., Antwi-Baffour, S., Jorfi, S., Kholia, S., Krige, L., Lange, S., Inal, J.M. (2012) Isolation of microvesicles and exosomes by filtration and estimation of normal reference range in blood plasma. Journal of Extracellular Vesicles Vol 1, Abstract 18  
  • Inal, J.M., Ansa-Addo, E.A., Cestari, I., Pathak, P., McCrossan, M.V., Lange, S., Ramirez, M. (2012) The intracellular parasite, Trypanosoma cruzi, utilises microvesicle release to invade host cells. Journal of Extracellular Vesicles Vol 1, Abstract 42
  • Stratton, D.*, Antwi-Baffour, S., Williams, G., Grant, R., Lange, S., Inal, J. M. (2012) Characterisation of microvesicles released from cells constitutively and upon stimulation. Journal of Extracellular Vesicles Vol. 1, pg 2 (*oral presentation)
  •  99th American Association of Immunologists meeting, Boston
  • Jorfi, S., Ansa-Addo, E.A., Lange, S., Inal, J.M. (2012) Coxsackie virus entry and spread in HeLa cells is aided by microvesicle release. J. Immunol. 188 Abstract 1336293.
  • Stratton, D., Antwi-Baffour, S., Grant, R., Inal, J.M. (2012) Two subtypes of Plasma Membrane-derived Vesicles can be isolated from tissue culture. J. Immunol. 188 Abstract 1336625.
  • Stratton, D., Inal, J.M. (2012) The two main PMV subtypes are significantly different in construction and have different physiological roles J. Immunol. 188 Abstract 1336686. 
  • Ansa-Addo, E. and Inal, J.M. (2010) Host cell release of plasma membrane-derived vesicles, causes damage to the cytoskeleton and leads to activation of Ca²+ -regulated lysosomal repair. Immunol. 131, 83 Presented at the British Society for Immunology meeting, Liverpool, December 2010
  • Jorfi, S., Ansa-Addo, E., and Inal, J.M (2010) Plasma Membrane-derived Vesicles released from infected HeLa cells by Coxsackie virus B1 induce apoptosis in recipient viable cells. Immunol. 131, 85 Presented at the British Society for Immunology meeting, Liverpool, December 2010
  • Ansa-Addo, E., and Inal J.M (2010) Trypanosoma cruzi utilisation of host cell membrane repair mechanisms aid invasion. Immunol. 131, 84 Presented at the British Society for Immunology meeting, Liverpool, December 2010
  • Stratton, D. and Inal, J.M (2010) Characterisation of cPMVs and sPMVs, constitutive and stimulated Plasma Membrane-derived Vesicles. Immunol. 131, 135 Presented at the British Society for Immunology meeting, Liverpool, December 2010
  • Euroscicon meeting 'Flow Cytometry Instrumentation and techniques; keeping up with the Changes', 2010
  • Ansa-Addo, E.A. and Inal, J.M. (2010) Plasma Membrane-derived vesicles carry TGF-β1 and promote adhesion and differentiation of THP-1 monocytes to macrophages. British Society for Parasitology Spring Meeting, Cardiff, 2010
  • Cestari, I.S., Ansa-Addo, E., Neto, L., Inal, J.M &Ramirez, M.I. (2010) A novel mechanism to resist complement lysis and invade host: cell triggered by Trypanosoma cruzi 97th American Association of Immunologists meeting, Baltimore
  • Ansa-Addo, E.A., and INAL, J.M. (2010) T. Cruzi Interference With Host Cell Membrane Integrity Triggers The Release Of PMVs: A Mechanism For Entry Into Mammalian Cells. J. Immunol. 184, 137.1     
  • Ansa-Addo, E.A. and INAL, J.M. (2010) Plasma membrane-derived vesicles, promote adhesion and differentiation of THP-1 monocytes in a TGF-β dependent manner. J. Immunol. 184, 35.15
  • Antwi-Baffour, S., Kholia, S., and INAL, J.M. (2010) aPLA antibodies promote the release of plasma membrane-derived vesicles which inhibit the phagocytosis of apoptotic cells – role in Systemic Lupus Erythematosus J. Immunol. 184, 135.9
  • Jorfi, S., Ansa-Addo, E.A., and INAL, J.M. (2010) Plasma membrane-derived Microvesicles (PMVs) released from apoptotic Jurkat cells express upregulated surface Fas and induce apoptosis in recipient viable cells. J. Immunol. 184, 89.45. Presented at the 96th American Association of Immunologists meeting, Seattle
  • Cestari, I.d.S, Ansa-Addo, E., Ramirez, M.I. and INAL, J.M. (2009) Trypanosoma cruzi induce blood cells to release microvesicles that inhibit complement lysis and promote cell invasion. Presented at the 25th Annual Meeting of the Brazilian Society of Protozoology/36th Annual Meeting on Chagas’ Disease, 23rd-28th August, 2009
  • Ansa-Addo, E.A., dos Santos Cestari, I., Pathak, P., Ramirez, M.I., INAL, J.M. (2009) Monocytic THP-1 cells stimulated by normal human serum (NHS) release cytokine-bearing plasma membrane-derived vesicles (PMVs), and can be inhibited by methyl-beta-cyclodextrin, calpeptin and Rho-kinase inhibitor, Y-27632. J. Immunol.182, 98.27
  • Cestari, I.d.S., Ansa-Addo, E., INAL, J.M., and Ramirez, M.I (2008) Trypanosoma cruzi release plasma membrane-derived vesicles (PMVs) to avoid lysis by the complement.
  • 22nd International Complement Workshop, Basel, 28th Sept - 2nd October, 2008
  • Cestari, I.d.S, Ansa-Addo, E ; INAL, J. M., and Ramirez, M.I (2008) Trypanosoma cruzi release plasma membrane-derived vesicles (PMVs) to avoid lysis by the complement  Presented at the 24th Annual Meeting of the Brazilian Society of Protozoology/35th Annual Meeting on Chagas disease research 27-29th October, 2008
  • dos Santos Cestari, Ansa-Addo, E., Pathak, P., Ramirez, M. and INAL, J.M. (2008) The intracellular Trypanosoma cruzi induces the release from monocytesof plasma membrane-derived microvesicles which protect the parasite from host complement. Mol. Immunol. 45:4173 British Society of Parasitology meeting, Newcastle, 30th March - 2nd April, 2008
  • dos Santos Cestari, INAL, J.M., Ramirez, M.I. (2008) Characterization of complement lectin pathway in Trypanosoma cruzi. (British Society of Parasitology meeting, Newcastle)
  • Lange, S., Hui, K.-M., Schifferli, J.A., and INAL, J.M. (2007) The complement regulatory receptor CRIT is expressed in the developing kidney. Mol. Immunol. 44:3991.
  • INAL, J.M., dos S. Cestari, I., Evans-Osses, I., Freitas, J.C., and Ramirez, M.I. (2007) The C2 receptor CRIT protects Trypanosoma cruzi against classical and MBL-directed, but not alternative pathway complement activation. J. Immunol. 178, 51.14.
  • INAL, J.M., and Rock, P.  (2007) Passive immunity against infection with Trypanosoma brucei subsp. brucei in mice is conveyed by an antibody blocking the ligand-binding extracellular domain 1 (ed1) of the C2 receptor CRIT. J. Immunol. 178, 47.20.
  • INAL, J.M., Wintergerst, E.S, Lange, S., Shamshiev, A., and Schifferli, J.A.  (2007) Complement C2 and CRIT are involved in the terminal differentiation of monocytes. J. Immunol. 178, 83.17.
  • INAL, J.M., Laich, A., and Miot, S. (2007) Complement C2 bypass mechanism involving the C3-convertase C4bBb. J. Immunol.178, 53.16.
  • Cestari, I., Evans-Osses, I.S., Hui, K.-M., INAL, J.M., and Ramirez, M.I. (2006) Mechanism of lectin complement pathway activation by T. cruzi. (11th Int. Conference of Parasitology ICOPA XI, Glasgow, Aug 2006).
  • #Hui, K.M., Orriss, G.L., Schirmer, T., Magnadottir, B., Schifferli, J.A, and INAL, J.M.  (2006)
  • Expression of functional recombinant von Willebrand factor-A domain from human complement C2: Potential binding site for C4 and CRIT. Mol. Immunol. 43: 126. (Student poster prize at 10th European Meeting on Complement in Health and Disease).
  • INAL, J.M., Miot, S. and Schifferli, J.A. (2006) Internalization of complement C2 receptor, CRIT, via a clathrin pathway. Mol. Immunol. 43: 157. (10th European Meeting on Complement in Health and Disease).
  • Cestari, I. dos S., Evans-Osses, I., INAL, J.M., and Ramirez, M.I. (2005) Mechanism of complement lectin pathway activation by Trypanosoma cruzi. (Merit prize at 21st Annual Meeting of the Brazilian Society of Protozoology, Caxambu, Brasil).
  • INAL, J.M., Hui, K.-M., Miot, S., Schneider, B., and Schifferli, J. (2004) Human Complement C2 receptor inhibitor trispanning (CRIT) regulates the classical pathway of complement activation. Mol. Immunol 41: 247. 
  • INAL, J.M., Hui, K.-M., Miot, S., Lange, S., Ramirez, M.I., Schneider, B., Krueger, G., and Schifferli, J.A. (2004) Human Complement C2 receptor inhibitor trispanning (CRIT): structural features and tissue distribution. Mol. Immunol. 41: 248. 
  • INAL, J.M., Hui, K.M., and Schifferli, J.A. (2003) CRIT-based and C4 -chain but not - nor -chain peptides inhibit classical pathway complement activation. Mol. Immunol. 40: 201-202 (9th European meeting on Complement in Human Disease, September 2003, Trieste).
  • Lange, S.* and INAL, J. (2003) CRIT (Complement C2 Receptor Inhibitor Trispanning) is found in cod (Gadus Morhua). (9th International Soc. for Developmental & Comparative Immunology congress, July 2003, St. Andrews).
  • INAL, J.M., et al. (2002) CRIT-H17 peptide inhibits inflammation in the reversed passive Arthus reaction. Int. Immunopharmacol. 2: 218, 1372.  (19th International Complement Workshop, September 2003, Palermo).
  • Ramirez, M.*, de Freitas, J.C., Cestari, I. and INAL, J. (2002) Dissecting the mechanism of resistance to complement-mediated lysis in Trypanosomatids.
  • INAL J.M. and Schifferli J.A. (2001) C4 -chain peptide interferes with the formation of the classical pathway 
  • C3 convertase. Mol. Immunol. 38: 97 (8th European meeting on Complement in Human Disease, September 2001, Strasbourg).
  • Wilkinson, G.W.G., Jacobs, S.C., Akrigg, A., INAL, J. and Stephenson, J.R. (1991) Constitutive and inducible expression from the CMV major IE promoter in a defective adenovirus vector. This paper was presented at the SGM Virus Group meeting Churchill College, Cambridge 23-25 September, 1991.

Dr. Jameel M. Inal
Professor of Immunobiology
j.inal@londonmet.ac.uk